| 000 | 02033cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223031148.0 | ||
| 008 | 150302s2014 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aPh.D | ||
| 099 | _aCai01.08.06.Ph.D.2014.Ma.I | ||
| 100 | 0 | _aMai Mahmoud Zafer Mourad | |
| 245 | 1 | 0 |
_aInvestigation of extended spectrum beta - lactamases and metallo - beta lactamases produced by pseudomonas aeruginosa in cancer patients in Egypt / _cMai Mahmoud Zafer Mourad ; Supervised Magdy Ali Amin , Moh. Seif Eldin Ashour , Hadir Elmahallawy |
| 246 | 1 | 5 | _aدراسة للطيف الممتد الانزيمات بيتا لاكتميز و ميتالوبيتا لاكتميز المنتجة بواسطة عينات بكتريا السودومونس ايروجونوزا فى مرضى السرطان بمصر |
| 260 |
_aCairo : _bMai Mahmoud Zafer Mourad , _c2014 |
||
| 300 |
_a174 P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (Ph.D.) - Cairo University - Faculty of Pharmacy - Department of Microbiology and Immunology | ||
| 520 | _aPseudomonas aeruginosa is a common opportunistic and nosocomial pathogen that causes severe infections with a high mortality rate, especially in immune compromised patients or those with underlying diseases. The increasing prevalence of MDR P. aeruginosa isolates is a global health problem, because of the limitation in clinical treatment options. Nowadays, imtensive clinical use of carbapenems has caused the presence of carbapenem resistant P. aeruginosa populations | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aAntibiotic resistance | |
| 653 | 4 | _aMetallo - beta lactamase | |
| 653 | 4 | _aPseudomonas aeruginosa | |
| 700 | 0 |
_aHadir Elmahallawy , _eSupervisor |
|
| 700 | 0 |
_aMagdy Ali Amin , _eSupervisor |
|
| 700 | 0 |
_aMohamed Seif Eldin Ashour , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aNazla _eRevisor |
||
| 905 |
_aSamia _eCataloger |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c49638 _d49638 |
||